about
Magnetic core-shell nanoparticles for drug delivery by nebulizationHigh-frequency ultrasonic atomization for drug delivery to rodent animal models - optimal particle size for lung inhalation of difluoromethyl ornithine.Spray-dried microparticles containing polymeric micelles encapsulating hematoporphyrinInhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft modelInhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancerHigh-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies.Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.Pulmonary elimination rate of inhaled 99mTc-sestamibi radioaerosol is delayed in healthy cigarette smokers.Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanopartiHas nanotechnology led to improved therapeutic outcomes?Inhaled chemotherapy in lung cancer: future concept of nanomedicine.Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: a future dilemma for micro-oncology.Formulation and characterization of nanoliposomal 5-fluorouracil for cancer nanotherapy.Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel.Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunitiesPreparation of 5-fluorouracil nanoparticles by supercritical antisolvents for pulmonary delivery.Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer.Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.Pilot Study of Inhaled Aerosols Targeted via Magnetic Alignment of High Aspect Ratio Particles in Rabbits
P2860
Q28393991-AB7F2DFA-05FE-4319-96F0-330D04C06196Q30365894-95FE84FE-A4B7-41C3-AD3B-80C093F7473BQ33749484-216E8883-5CBA-4391-9F78-244E01D398C9Q33987004-B9477C8D-6ED7-4B23-9CEE-BEFEB0804E06Q34300257-9BECAAC3-D35E-4B13-BF10-B705746DE500Q34577430-CE6FB9B5-7734-4C2A-80C0-5E767DDA80EDQ35097949-F1C5EAC2-A2E5-4FFB-804B-F47CA0DEFFFCQ36536480-194F7297-B01A-4ACB-9545-A036396D4E70Q36555371-D67AA450-7AD4-4575-A3F7-70B9C37D8EDDQ37970730-61038C5D-3A23-4D2A-B39C-995FCFBE19E0Q38012447-F4CCE107-65E3-44D6-B17C-44E58DE5F153Q38096410-09E159D9-8FE2-4F09-9830-5E0FE87A7606Q39129060-035D9445-588F-4818-B0D6-7FBE656A996FQ39202347-4B0CFE90-9B6F-48D3-9297-A3C3F9EAC69BQ39306543-A2F7B861-AFBC-4A25-99CC-F278F0F4A321Q42057923-C0801D0F-8B3D-4817-953D-C8CA63D4692EQ46145077-F9CC6386-C391-4599-8142-19D8F501A289Q50034069-C0FDFB16-D1CE-4E42-99A8-640150FF717DQ58205745-3D46F43F-648B-4FAA-B6B5-D123D59D894F
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Development of inhalational agents for oncologic use.
@ast
Development of inhalational agents for oncologic use.
@en
Development of inhalational agents for oncologic use.
@nl
type
label
Development of inhalational agents for oncologic use.
@ast
Development of inhalational agents for oncologic use.
@en
Development of inhalational agents for oncologic use.
@nl
prefLabel
Development of inhalational agents for oncologic use.
@ast
Development of inhalational agents for oncologic use.
@en
Development of inhalational agents for oncologic use.
@nl
P2093
P1476
Development of inhalational agents for oncologic use
@en
P2093
P304
P356
10.1200/JCO.2001.19.6.1839
P407
P50
P577
2001-03-01T00:00:00Z